Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Research & Development: 2022-2025

Historic Research & Development for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $40.2 million.

  • Axsome Therapeutics' Research & Development fell 11.51% to $40.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.5 million, marking a year-over-year increase of 16.34%. This contributed to the annual value of $187.1 million for FY2024, which is 91.00% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Research & Development of $40.2 million as of Q3 2025, which was down 18.93% from $49.5 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Research & Development peaked at $55.0 million during Q4 2024, and registered a low of $12.6 million during Q1 2022.
  • Its 3-year average for Research & Development is $38.1 million, with a median of $40.2 million in 2025.
  • Its Research & Development has fluctuated over the past 5 years, first spiked by 142.23% in 2024, then fell by 11.51% in 2025.
  • Axsome Therapeutics' Research & Development (Quarterly) stood at $14.7 million in 2022, then soared by 109.64% to $30.8 million in 2023, then spiked by 78.57% to $55.0 million in 2024, then fell by 11.51% to $40.2 million in 2025.
  • Its Research & Development stands at $40.2 million for Q3 2025, versus $49.5 million for Q2 2025 and $44.8 million for Q1 2025.